BRIEF—Almirall launches Wynzora cream in Europe

Spanish dermatology specialist Almirall has announced the European commercial launch of Wynzora cream (calcipotriene and betamethasone dipropionate).

Developed for the topical treatment of mild to moderate plaque psoriasis in adults including scalp, the cream is first available in Europe in Spain, Germany, and the UK.

Almirall has boasted that the launch of Wynzora makes it the only biopharma in Europe to offer psoriasis patients multiple options covering the entire spectrum of the disease, from topicals to oral systemics and biologics.

In February 2021, Almirall and MC2 Therapeutics entered into a strategic agreement under which the Barcelona-based firm was granted exclusive European rights to commercialize Wynzora cream for treatment of plaque psoriasis. Both companies announced the successful completion of a decentralised procedure in July last year. The product is also commercialized in the USA in partnership with EPI Health.